Movement Alert｜Kelun-Biotech Biopharmaceutical Rises 3.12% in Regular Trading, ASCO Annual Meeting Data Continues to Catalyze Pipeline Value Reassessment

Market Focus

May 26

On May 26, Kelun-Biotech Biopharmaceutical rose 3.12% in regular trading, trading at 484.0 HKD/share, with trading volume of approximately 189 million HKD.

On the news front, the company has seen a series of R&D milestones driving momentum. Previously, the company announced that its core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) and RET inhibitor lunbotinib fumarate have both been selected for oral presentations at the metastatic non-small cell lung cancer session at the ASCO annual meeting. Notably, the Phase III OptiTROP-Lung05 study demonstrated that sac-TMT combined with pembrolizumab significantly extended progression-free survival versus pembrolizumab monotherapy in first-line PD-L1-positive advanced NSCLC, with an objective response rate of 70.2%. Additionally, the global Phase III TroFuse-005 study of sac-TMT in endometrial cancer successfully met both OS and PFS co-primary endpoints. China Post Securities also initiated coverage with a Buy rating, citing imminent global pipeline value realization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1116262705"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116262705\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116262705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116262705","market":"us","top_or_hot":-1,"title":"Movement Alert｜Kelun-Biotech Biopharmaceutical Rises 3.12% in Regular Trading, ASCO Annual Meeting Data Continues to Catalyze Pipeline Value Reassessment","media":"Market Focus","content":"<p><p>On May 26, Kelun-Biotech Biopharmaceutical rose 3.12% in regular trading, trading at 484.0 HKD/share, with trading volume of approximately 189 million HKD.</p><p>On the news front, the company has seen a series of R&D milestones driving momentum. Previously, the company announced that its core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) and RET inhibitor lunbotinib fumarate have both been selected for oral presentations at the metastatic non-small cell lung cancer session at the ASCO annual meeting. Notably, the Phase III OptiTROP-Lung05 study demonstrated that sac-TMT combined with pembrolizumab significantly extended progression-free survival versus pembrolizumab monotherapy in first-line PD-L1-positive advanced NSCLC, with an objective response rate of 70.2%. Additionally, the global Phase III TroFuse-005 study of sac-TMT in endometrial cancer successfully met both OS and PFS co-primary endpoints. China Post Securities also initiated coverage with a Buy rating, citing imminent global pipeline value realization.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Kelun-Biotech Biopharmaceutical Rises 3.12% in Regular Trading, ASCO Annual Meeting Data Continues to Catalyze Pipeline Value Reassessment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Kelun-Biotech Biopharmaceutical Rises 3.12% in Regular Trading, ASCO Annual Meeting Data Continues to Catalyze Pipeline Value Reassessment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-26 10:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 26, Kelun-Biotech Biopharmaceutical rose 3.12% in regular trading, trading at 484.0 HKD/share, with trading volume of approximately 189 million HKD.</p><p>On the news front, the company has seen a series of R&D milestones driving momentum. Previously, the company announced that its core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) and RET inhibitor lunbotinib fumarate have both been selected for oral presentations at the metastatic non-small cell lung cancer session at the ASCO annual meeting. Notably, the Phase III OptiTROP-Lung05 study demonstrated that sac-TMT combined with pembrolizumab significantly extended progression-free survival versus pembrolizumab monotherapy in first-line PD-L1-positive advanced NSCLC, with an objective response rate of 70.2%. Additionally, the global Phase III TroFuse-005 study of sac-TMT in endometrial cancer successfully met both OS and PFS co-primary endpoints. China Post Securities also initiated coverage with a Buy rating, citing imminent global pipeline value realization.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1116262705","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116262705","pubTimestamp":1779762011,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 26, Kelun-Biotech Biopharmaceutical rose 3.12% in regular trading, trading at 484.0 HKD/share, with trading volume of approximately 189 million HKD.On the news front, the company has seen a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"动向提示|科伦生物制药常规交易涨3.12%ASCO年会数据持续催化管线价值重估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On May 26, Kelun-Biotech Biopharmaceutical rose 3.12% in regular trading, trading at 484.0 HKD/share, with trading volume of approximately 189 million HKD.On the news front, the company has seen a series of R&D milestones driving momentum. Previously, the company announced that its core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) and RET inhibitor lunbotinib fumarate have both been selected for oral presentations at the metastatic non-small cell lung cancer session at the ASCO annual meeting. Notably, the Phase III OptiTROP-Lung05 study demonstrated that sac-TMT combined with pembrolizumab significantly extended progression-free survival versus pembrolizumab monotherapy in first-line PD-L1-positive advanced NSCLC, with an objective response rate of 70.2%. Additionally, the global Phase III TroFuse-005 study of sac-TMT in endometrial cancer successfully met both OS and PFS co-primary endpoints. China Post Securities also initiated coverage with a Buy rating, citing imminent global pipeline value realization.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}